Ophthalmic Consultants of Boston | Boston, MA

Research site
50 Staniford Street, Boston, Massachusetts, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


21 of 118
Status: Active
Trial type: Interventional
Funder type: Industry

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Indeterminate Lesions
Ocular Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Crizotinib
Drug: Lorlatinib

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This main long-term extension study is designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Other: Sham Procedure
Drug: Faricimab

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in subjects with Neovascular (wet) Ag...

Diabetic Macular Edema
Neovascular Age-related Macular Degeneration
Drug: D-4517.2
Recently updated

This is a multicenter, open-label, dose escalation (Cohort 1) to masked, randomized, parallel-groups (Cohort 2) and (Cohort 3) study to evaluate the...

Open-angle Glaucoma
Ocular Hypertension
Other: Lumigan Vehicle
Other: Lumigan

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration

This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combinat...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: encorafenib
Drug: binimetinib

Patients who completed Study ISEE2008 (GATHER2) and consent to participate will be administered monthly avacincaptad pegol 2 mg.

Active, not recruiting
Macular Degeneration
Geographic Atrophy
Drug: Avacincaptad pegol 2 mg intravitreal injection

This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained rele...

Active, not recruiting
Open-Angle Glaucoma
Ocular Hypertension
Drug: Bimatoprost (SR)

This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovas...

Neovascular Age-Related Macular Degeneration
Drug: PDS Implant with Ranibizumab 100 mg/mL

This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who wer...

Wet Macular Degeneration
Neovascular Age-related Macular Degeneration
Genetic: RGX-314

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Wet Age-related Macular Degeneration
Genetic: RGX-314 Dose 2
Biological: Aflibercept (EYLEA®)

RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of diabetic retinopathy, a chronic and progressive...

Diabetic Retinopathy (DR)
Drug: Topical Steroid
Genetic: RGX-314 Dose 1

In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) i...

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lowe...

Active, not recruiting
Geographic Atrophy
Age-related Macular Degeneration
Biological: VOY-101

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerab...

Age-Related Macular Degeneration
Drug: Placebo Comparator
Drug: Active Comparator CT1812

This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU...

Active, not recruiting
Diabetic Macular Edema
Drug: CU06-1004

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic...

Active, not recruiting
Diabetic Macular Edema
Drug: Intravitreal Ranibizumab 0.5 mg Injection
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Trial conditions

Macular Degeneration (45 trials)
Macular Edema (32 trials)
Edema (25 trials)
Geographic Atrophy (16 trials)
Atrophy (13 trials)
Uveitis (11 trials)
Diabetic Retinopathy (9 trials)
Wet Macular Degeneration (9 trials)
Retinal Vein Occlusion (7 trials)
Anterior Uveitis (6 trials)

And 39 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems